Related Experiment Video
Updated: Jul 12, 2025
Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
Published on: March 8, 2024
Interleukin-6 and Its Soluble Receptor Complex in Intensive Care Unit COVID-19 Patients: An Analysis of Second Wave
Gaetano Di Spigna1, Daniela Spalletti Cernia1, Bianca Covelli1
1Department of Translational Medical Sciences, University of Naples "Federico II", 80131 Naples, Italy.
Insights
Elevated interleukin-6 (IL-6) levels and its soluble receptors in severe COVID-19 patients correlate with disease severity and mortality. These biomarkers may predict outcomes in critically ill patients, aiding in disease management.
Area of Science:
- Immunology
- Virology
- Critical Care Medicine
Background:
- The COVID-19 pandemic, caused by SARS-CoV-2, has led to significant global mortality.
- Hyperinflammation, particularly elevated interleukin-6 (IL-6) levels, is linked to severe COVID-19 and increased mortality.
- Understanding the role of IL-6 and its receptor complex in severe respiratory failure is crucial.
Purpose of the Study:
- To analyze serum levels of IL-6, soluble IL-6 receptor (sIL-6R), and soluble glycoprotein 130 (sgp130) in critically ill COVID-19 patients during the second wave.
- To investigate the correlation between these biomarkers and disease severity, respiratory failure, and clinical outcomes.
- To evaluate the potential of IL-6 and its receptor complex as prognostic markers for severe COVID-19.
Main Methods:
- Serum samples from critically ill COVID-19 patients with severe respiratory failure were analyzed.
- Chemiluminescent immunoassay was used to determine IL-6 concentrations.
- Enzyme-linked immunosorbent assay (ELISA) was employed to detect serum levels of sIL-6R and sgp130.
Main Results:
- Serum IL-6 levels were significantly elevated in severe COVID-19 patients, consistent with findings from the first wave.
- Higher concentrations of IL-6 correlated with increased disease severity and adverse clinical outcomes.
- Elevated levels of sIL-6R and sgp130 were also observed in more severe cases.
Conclusions:
- Interleukin-6 and its soluble receptor complex are significantly associated with severe COVID-19 and poor prognosis.
- These molecules serve as potential predictive markers for disease progression, severity, and mortality in critically ill COVID-19 patients.
- Further research into targeted therapies modulating the IL-6 pathway may be warranted for severe COVID-19 cases.
Abstract:
In December 2019, a SARS-CoV-2 virus, coined Coronavirus Disease 2019 (COVID-19), discovered in Wuhan, China, affected the global population, causing more than a million and a half deaths. Since then, many studies have shown that the hyperinflammatory response of the most severely affected patients was primarily related to a higher concentration of the pro-inflammatory cytokine interleukin-6, which directly correlated with disease severity and high mortality. Our study analyzes IL-6 and its soluble receptor complex (sIL-6R and sgp130) in critically ill COVID-19 patients who suffered severe respiratory failure from the perspective of the second COVID wave of 2020. A chemiluminescent immunoassay was performed for the determination of IL6 in serum together with an enzyme-linked immunosorbent assay to detect serum levels of sIL-6R and sgp130, which confirmed that the second wave's serum levels of IL-6 were significantly elevated in the more severe patients, as with the first 2019 COVID-19 wave, resulting in adverse clinical outcomes. At present, considering that no specific treatment for severe COVID-19 cases in its later stages exists, these molecules could be considered promising markers for disease progression, illness severity, and risk of mortality.
Related Concept Videos
01:29Pneumonia II: Pathophysiology
01:21Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include: